200 related articles for article (PubMed ID: 33008498)
1. Application of Single-Cell Sequencing to Immunotherapy.
Beaumont KG; Beaumont MA; Sebra R
Urol Clin North Am; 2020 Nov; 47(4):475-485. PubMed ID: 33008498
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options.
Chakravarty D; Huang L; Kahn M; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4):487-510. PubMed ID: 33008499
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
Gill DM; Agarwal N
Urol Oncol; 2017 Dec; 35(12):676-677. PubMed ID: 29054496
[TBL] [Abstract][Full Text] [Related]
7. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
Bryant G; Wang L; Mulholland DJ
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714919
[TBL] [Abstract][Full Text] [Related]
9. [Optimizing treatment of advanced urologic malignancies].
Heidenreich A; Ohlmann CH; Ozgür E; Pfister D; Sahi D; Thüer D; Engelmann UH
Urologe A; 2007 Sep; 46(9):1278-84. PubMed ID: 17628781
[No Abstract] [Full Text] [Related]
10. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
11. Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art.
Pantuck M; Palaskas N; Drakaki A
Cancer Treat Res Commun; 2018; 17():8-12. PubMed ID: 30173005
[No Abstract] [Full Text] [Related]
12. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
Patel D; McKay R; Parsons JK
Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in immuno-oncology and its application to urological cancers.
Mataraza JM; Gotwals P
BJU Int; 2016 Oct; 118(4):506-14. PubMed ID: 27123757
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy in the treatment of genitourinary cancers].
Géczi L; Ladányi A; Vajdics T; Küronya Z; Bíró K; Gyergyay F; Martin T; Nagyiványi K
Magy Onkol; 2016 Mar; 60(1):41-5. PubMed ID: 26934350
[TBL] [Abstract][Full Text] [Related]
16. Molecular research in cancer: future clinical applications.
Ratliff TL
Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
[No Abstract] [Full Text] [Related]
17. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Ikeda S; Hansel DE; Kurzrock R
Cancer Treat Rev; 2015 Sep; 41(8):699-706. PubMed ID: 26138514
[TBL] [Abstract][Full Text] [Related]
18. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy approaches in urologic oncology.
Vieweg J; Gilboa E
Surg Oncol Clin N Am; 1995 Apr; 4(2):203-18. PubMed ID: 7796281
[TBL] [Abstract][Full Text] [Related]
20. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.
Gerlinger M; Catto JW; Orntoft TF; Real FX; Zwarthoff EC; Swanton C
Eur Urol; 2015 Apr; 67(4):729-37. PubMed ID: 24836153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
